Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 ...

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study ...

Imunon, Inc. ( NASDAQ: IMNN) Q2 2025 Earnings Conference Call August 5, 2025 11:00 AM ET Douglas V. Faller - Chief Medical Officer Khursheed Anwer - Executive VP & Chief Scientific Officer Kimberly ...

The current quarter introduced the 15% onetime stock dividend and confirmed accelerated site activation for OVATION 3, compared to the previous quarter's focus on initial site readiness and ...

Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a ...

Analysts expect Imunon to report an earnings per share (EPS) of $-3.09. The market awaits Imunon's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the ...

Shares of IMUNON are trading higher Wednesday morning. The company announced a clinical milestone for its lead drug candidate, IMNN-001.

Imunon, Inc. (($IMNN)) announced an update on their ongoing clinical study. Imunon, Inc. is conducting a Phase 3 clinical trial titled A ...

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), ...

At its annual meeting, Imunon shareholders approved an increase in authorized shares from 112.5 million to 350 million and authorized a reverse stock split, with the exact ratio to be determined ...

--IMUNON, Inc., a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced a reverse stock split of its issued and outstanding common stock, par value $0.01 ...

IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized ...